TY - JOUR
T1 - Long-term efficacy and safety of eculizumab in Japanese patients with PNH
T2 - AEGIS trial
AU - Kanakura, Yuzuru
AU - Ohyashiki, Kazuma
AU - Shichishima, Tsutomu
AU - Okamoto, Shinichiro
AU - Ando, Kiyoshi
AU - Ninomiya, Haruhiko
AU - Kawaguchi, Tatsuya
AU - Nakao, Shinji
AU - Nakakuma, Hideki
AU - Nishimura, Jun Ichi
AU - Kinoshita, Taroh
AU - Bedrosian, Camille L.
AU - Ozawa, Keiya
AU - Omine, Mitsuhiro
N1 - Funding Information:
Conflict of interest YK has received research funding and been a consultant and board member for Alexion Pharmaceuticals. H. Ninomiya has received honoraria for lectures from Alexion Pharmaceuticals. T. Kawaguchi has received honoraria for lectures from Alexion Pharmaceuticals and works for an institution that has received research funding from Alexion Pharmaceuticals. SN works for an institution that has received research support from Alexion Pharmaceuticals. H. Nakakuma has received honoraria for lectures from Alexion Pharmaceuticals. J-IN has received research grants from and been a consultant and board member for Alexion Pharmaceuticals. T. Kinoshita has received honoraria for lectures from Al-exion Pharmaceuticals. CLB is an employee of and owns stock in Alexion Pharmaceuticals. MO has received consulting fees/honoraria, travel support, and payments for development of educational presentations from Alexion Pharmaceuticals. K. Ohyashiki, TS, SO, KA, and K. Ozama have no conflicts of interest to declare.
Funding Information:
Acknowledgments The authors would like to thank Gus Khursig-ara, PhD, for providing insightful comments on the manuscript; Masakazu Hase, PhD, for assistance with coordinating the manuscript preparation; and Mark Hughes, PhD, and Joshua Safran of Infusion Communications for writing and editorial support, which was funded by Alexion Pharmaceuticals.
PY - 2013/10
Y1 - 2013/10
N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive hematopoietic stem cell disorder characterized by chronic complement-mediated hemolysis leading to life-threatening complications and early mortality. Eculizumab, a humanized anti-C5 monoclonal antibody, inhibits terminal complement activation, reduces hemolysis, decreases the risk of thrombosis, and improves renal function and quality of life in PNH patients. The long-term efficacy and safety of eculizumab in Japanese patients were assessed in a 2-year extension to a 12-week, open-label study (AEGIS). Eculizumab treatment led to an immediate and sustained reduction in intravascular hemolysis (P < 0.001) and red blood cell transfusions (P = 0.0016) compared with baseline levels. There were no reports of thromboembolism during eculizumab treatment. The majority of patients had stable (56 %) or improved (41 %) renal function and an improved quality of life (P = 0.015), with sustained reductions in fatigue and dyspnea. Eculizumab was well tolerated; no deaths or serious hemolytic events were reported, and the rate of infections declined over time. There were no significant differences in the response to eculizumab in patients with or without bone marrow dysfunction. These results demonstrate that eculizumab is an effective, well-tolerated long-term treatment for Japanese PNH patients and leads to continued amelioration of some hemolytic complications.
AB - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive hematopoietic stem cell disorder characterized by chronic complement-mediated hemolysis leading to life-threatening complications and early mortality. Eculizumab, a humanized anti-C5 monoclonal antibody, inhibits terminal complement activation, reduces hemolysis, decreases the risk of thrombosis, and improves renal function and quality of life in PNH patients. The long-term efficacy and safety of eculizumab in Japanese patients were assessed in a 2-year extension to a 12-week, open-label study (AEGIS). Eculizumab treatment led to an immediate and sustained reduction in intravascular hemolysis (P < 0.001) and red blood cell transfusions (P = 0.0016) compared with baseline levels. There were no reports of thromboembolism during eculizumab treatment. The majority of patients had stable (56 %) or improved (41 %) renal function and an improved quality of life (P = 0.015), with sustained reductions in fatigue and dyspnea. Eculizumab was well tolerated; no deaths or serious hemolytic events were reported, and the rate of infections declined over time. There were no significant differences in the response to eculizumab in patients with or without bone marrow dysfunction. These results demonstrate that eculizumab is an effective, well-tolerated long-term treatment for Japanese PNH patients and leads to continued amelioration of some hemolytic complications.
KW - Complement-inactivating agents
KW - Eculizumab
KW - Hematopoietic stem cell
KW - Hemolysis
KW - Paroxysmal nocturnal hemoglobinuria
UR - http://www.scopus.com/inward/record.url?scp=84886803820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886803820&partnerID=8YFLogxK
U2 - 10.1007/s12185-013-1404-y
DO - 10.1007/s12185-013-1404-y
M3 - Article
C2 - 23934275
AN - SCOPUS:84886803820
SN - 0925-5710
VL - 98
SP - 406
EP - 416
JO - International journal of hematology
JF - International journal of hematology
IS - 4
ER -